Analysts expect CRISPR Therapeutics AG to report revenue of 14.25 M for Q3 26, against a range of 13.80 M to 14.71 M. The most recent reported quarter, Q2 26, came in at 10.18 M, a 44.5% beat against the 7.04 M consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 602,000.00 | 35.69 M | 865,000.00 | 892,000.00 | 889,000.00 | 864,000.00 | 1.46 M | 10.18 M | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | 7.37 M | 8.65 M | 7.05 M | 6.32 M | 10.13 M | 5.39 M | 6.16 M | 7.52 M | 14.71 M | 14.60 M | 20.21 M | 20.77 M | 45.99 M | 108.53 M | 48.39 M | 89.58 M | ||||||||||
| Low Estimate | 6.32 M | 7.08 M | 6.24 M | 5.17 M | 9.25 M | 4.66 M | 5.60 M | 6.57 M | 13.80 M | 13.01 M | 16.79 M | 18.80 M | 42.00 M | 94.27 M | 44.09 M | 79.72 M | ||||||||||
| Consensus Estimate | 6.85 M | 7.87 M | 6.65 M | 5.74 M | 9.69 M | 5.03 M | 5.88 M | 7.04 M | 14.25 M | 13.80 M | 18.50 M | 19.78 M | 43.99 M | 101.40 M | 46.24 M | 84.65 M |
Analysts expect CRISPR Therapeutics AG to report earnings per share of -1.11 for Q3 26, against a range of -1.18 to -1.04. The most recent reported quarter, Q2 26, came in at -0.94, a 23.0% beat against the -1.22 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -1.01 | -0.44 | -1.58 | -2.40 | -1.17 | -1.37 | -1.28 | -0.94 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | -1.23 | -1.10 | -1.22 | -1.39 | -1.13 | -1.13 | -1.07 | -1.15 | -1.04 | -1.09 | -0.81 | -0.80 | -0.60 | -0.83 | -0.71 | -0.48 | ||||||||||
| Low Estimate | -1.47 | -1.18 | -1.32 | -1.59 | -1.21 | -1.27 | -1.25 | -1.29 | -1.18 | -1.27 | -0.87 | -0.86 | -0.68 | -0.95 | -0.83 | -0.52 | ||||||||||
| Consensus Estimate | -1.35 | -1.14 | -1.27 | -1.49 | -1.17 | -1.20 | -1.16 | -1.22 | -1.11 | -1.18 | -0.84 | -0.83 | -0.64 | -0.89 | -0.77 | -0.50 |
Pull Wall Street consensus for CRISPR Therapeutics AG (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=CRSP&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "CRSP", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=CRSP&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();